Skip to Main Content

Paper Details

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.
Haematologica
67
2021
Author NameAffiliation
Jorge CortesUniversity of Texas MD Anderson Cancer Center
Farhad RavandiUniversity of Texas MD Anderson Cancer Center
Guillermo Garcia-ManeroUniversity of Texas MD Anderson Cancer Center
Gautam BorthakurUniversity of Texas MD Anderson Cancer Center
Steven M KornblauUniversity of Texas MD Anderson Cancer Center
Qingyi WeiUniversity of Texas MD Anderson Cancer Center
Hagop KantarjianUniversity of Texas MD Anderson Cancer Center
Courtney D DiNardoUniversity of Texas MD Anderson Cancer Center
  • 1 - 8

Datasets

Release 1.2